Solorank.ai
Login

Cached score snapshot

US.KVUE · Kenvue

110分制 44.3/110；5D動能v2 11/50；排序分 55.3/160 · Incomplete inputs

Back to ranking Open volume snapshot
Ranking score 55.3/160
Main score 44.3/110
5D momentum v2 11/50
Rank #148
Setup grade F 27.3

Score breakdown

避免

Medium twelvedata

Score and price trend

F 27.3 Low sample confidence

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 06-22 08-04 09-16 10-07 10-27 $16.77$18.57$20.38 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.38 · anchors 120 +0.63% -1.67% / +2.53% 57.5% 6.3% Actual outcome pending · 0 / 3 bars observed
30D observation +1.39% -1.68% / +4.43% 61.3% 10% Actual outcome pending · 0 / 30 bars observed
Historical projection 10D n=160 +0.29% -1.59% / +2.09% 53.1% 4.4% Actual outcome pending · 0 / 10 bars observed

歷史情境統計基於已存檔相似 setup；圖中投影中位線為統計中位數的線性插值展示，並非價格路徑預測或買賣建議。

2026-06-22 → 2026-10-27 · 120 archived points · 3 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 55.3
Display grade 避免
Model version cursor_18_27_news_v2_160
Main score 44.3/110 (避免)
5D momentum v2 11/50 (弱)
Score with momentum v2 55.3/160 (低排序)
Risk level Medium

Audit trace

Full calculation detail

Calculation detail · 8 sections

Incomplete score

此 snapshot 已計出評分，但以下輸入仍不完整；缺失維度以 0 分處理，請留意 audit 明细。

  • VIX_MISSING: VIX market context is required for market environment scoring

Market inputs

Bar count 60
ma20 18.713
ma50 19.0096
close 17.92
prevClose 17.91
avgVolume20 27110310
volumeRatio 1.99
changePercent 0.06

Metrics snapshot

close 17.92
volume 53824402
changePercent 0.06

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 44.3/110
Main rating 避免
5D momentum v2 11/50
Score with momentum v2 55.3/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 4.1/5 · 優秀
Dimension score 4.1/5
Dimension grade 優秀

Sub-items

pbPoints 0.4
pePoints 0.4
epsPoints 0.75
roePoints 0.6
debtPoints 0.4
marginPoints 0
turnoverUsdM 964.5333
volumePoints 0.5
revenuePoints 0
dividendPoints 0.5
marketCapPoints 0.5

資金流 — 8.4/20 · 較差
Dimension score 8.4/20
Dimension grade 較差

Sub-items

cmfPoints 0.8
mfiPoints 0.8
obvPoints 4
vwapPoints 0.8

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.KVUE
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 5.6/15 · 較差
Dimension score 5.6/15
Dimension grade 較差

Sub-items

vix

score 0

details

source twelvedata+fred
missing true
vixClose n/a

trend

score 0.8

details

qqq

ma20 713.307
ma50 709.9724
name QQQ
close 704.54
points 0.4

spy

ma20 765.342
ma50 759.0606
name SPY
close 757.39
points 0.4
source twelvedata+fred
atrPct 1.9018
atrPoints 4
cciPoints 0.8
vixPoints 0
marketTrendPoints 0.8

催化劑 — 2/20 · 較差
Dimension score 2/20
Dimension grade 較差

Sub-items

catalyst

score 2

details

source finnhub_news_keyword_model
articleCount 6
catalystCount 0
catalystPoints 2

風險管理 — 7.6/10 · 良好
Dimension score 7.6/10
Dimension grade 良好

Sub-items

position

score 1.8

details

atrPct 1.9018
turnoverUsdM 964.5333
liquidityPoints 0.6
volatilityPoints 1.2
rrPoints 1.4

stopLevels

symbol US.KVUE
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 17.2384

strength_details

ma_score 1
atr_score 2.5
rsi_score 2.5
macd_score 1
volume_score 2
market_adjustment 1
risk_reward_ratio 1.3
stop_loss_percent 3.8
take_profit_price 18.816
target_multiplier 1.9
technical_strength 1.73
take_profit_percent 5
positionPoints 1.8
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Consumer Staples
concentratedSectorPenalty 0
riskRewardRatio 1.3146
stopLossPercent 3.8036
diversificationPoints 2

技術信號 — 12.6/30 · 較差
Dimension score 12.6/30
Dimension grade 較差

Sub-items

bbPoints 2.4
adxPoints 3
sarPoints 1.2
vcpPoints 1.1
macdPoints 0.8

vcpPayload

vcp_pass false
vcp_score 1.1
vcp_reason 跌縮量(近10日3日)；升放量(近10日2日)；Ready=N；Confirm=Y

vcp_metrics

up_days 3
vol_ref 24144633.3333
down_days 6
vcp_ready false
above_ma50 false
avg_vol_10 30684510
avg_vol_20 25817575
avg_vol_30 24144633.3333
range_pct_10 0.0884
range_pct_20 0.1094
range_pct_30 0.1172
up_expand_ok true
lookback_used 59
near_20d_high false
contraction_ok false
down_shrink_ok true
up_expand_days 2
breakout_20d_ok false
vol_ratio_10_30 1.2709
dist_to_20d_high 0.0838
down_shrink_days 3
breakout_level_20d 19.56
vcp_breakout_confirm true
contraction_ratio_10_30 0.7548
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction false
kdjAdxPoints 0.7
rsiKdjPoints 0.8
volumeWeight 2
maCrossPoints 0
shortRsiPoints 0
shortMacdPoints 0.4
volConfirmPoints 1
volumePointsTechnical 1.2

情緒分析 — 4/10 · 較差
Dimension score 4/10
Dimension grade 較差

Sub-items

sentiment

score 4

details

source finnhub_news_keyword_model
articleCount 6
negativeHits 0
positiveHits 2
sentimentScoreRaw 0.8

sentimentData

raw {"id":142166216,"url":"https://finnhub.io/api/news?id=0b01c4efa9a88f652753ccd0bb270fdd7f39647ec9bffff2d7f3f3f8dbbb41e4","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Kenvue Inc. previously announced that its Board of Directors declared a quarterly dividend of US$0.21 per share, payable on October 2, 2026, to shareholders of record as of September 21, 2026, while also securing FDA approval for TYLENOL with Naproxen, a first-of-its-kind non-opioid OTC pain reliever backed by multiple clinical studies. By pairing a new, clinically supported TYLENOL with Naproxen launch with ongoing cash returns via dividends, Kenvue is highlighting both product innovation...","category":"company","datetime":1789492334,"headline":"Should Kenvue’s (KVUE) TYLENOL with Naproxen Launch and Dividend Plan Prompt Investor Reassessment?"}, {"id":142166217,"url":"https://finnhub.io/api/news?id=6001775f3a84f88a94e43e27d5847522896be1df7e3e8fa648fd7f246df94a34","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Kenvue (KVUE) is on investors’ radar after launching TYLENOL with Naproxen, an FDA-approved, opioid-free over the counter pain reliever that combines acetaminophen and naproxen sodium, backed by extensive clinical research. That launch comes as Kenvue’s share price has softened in the short term, with a 7 day share price return of down 4.43% and a 30 day share price return of down 6.72%. Even though the year to date share price return is 3.41% and the 1 year total shareholder return is 2.85%,...","category":"company","datetime":1789485377,"headline":"Is Kenvue (KVUE) A Bargain Following Its TYLENOL With Naproxen Launch?"}, {"id":141771435,"url":"https://finnhub.io/api/news?id=c7fb779f54328c36dd6407d82131e651780d8d24dbeab0820fdfc8bbec803f7b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Kenvue's profit margins and cash flow improved in the first half, but modest sales growth, debt and uneven segment trends keep the risk-reward balanced.","category":"company","datetime":1788809160,"headline":"Should Investors Buy KVUE as Margin Gains Offset Slow Sales Growth?"}, {"id":141282754,"url":"https://finnhub.io/api/news?id=d6e8702ffd287b3173c9163b137bb8ec42a1739ff848e40850de334af327d7ca","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Kenvue stock has delivered a 9.3% gain year to date. Its current share price of US$18.93 still sits well below an intrinsic value estimate from a Discounted Cash Flow (DCF) model, which points to a 36.4% discount. At the same time, traditional earnings multiples suggest the shares look about fairly priced, leaving investors weighing a clear DCF upside signal against more neutral market ratios. Year to date, Kenvue is up 9.3%, indicating the market has already repriced the stock higher even...","category":"company","datetime":1787292615,"headline":"Kenvue (KVUE) Stock Looks Cheap On Cash Flow But Fair On Earnings"}, {"id":141282755,"url":"https://finnhub.io/api/news?id=a45b9ab18c80eae5ef52d4897040a916581758913448bcfaed72ddb23667f08f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"In August 2026, Kenvue’s Zyrtec brand launched Zyrtec Allergen Shield Spray, a drug-free nasal mist that forms a gel barrier in the nose within minutes to help block common airborne allergens like pollen, pet dander, and dust for up to six hours in adults and children aged 12 and older. This first-of-its-kind, HPMC-based spray expands Zyrtec’s toolkit toward proactive allergen defense, signaling Kenvue’s push into drug-free, preventative allergy solutions. We’ll now examine how this new...","category":"company","datetime":1787271185,"headline":"Should Zyrtec’s New Drug-Free Allergen Shield Spray Launch Require Action From Kenvue (KVUE) Investors?"}, {"id":141282756,"url":"https://finnhub.io/api/news?id=f7e9f9af2724ae75a24bbee4208fcfc80ce1a514f2e2f949f1a3e6ffa79e11d9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Zyrtec Allergen Shield Spray, a new drug free nasal mist from Kenvue (KVUE), has given investors fresh product news to weigh. The launch highlights activity in the company’s Self Care allergy portfolio. See our latest analysis for Kenvue. The recent Zyrtec Allergen Shield Spray launch comes after Kenvue reported second quarter 2026 sales of US$3,955 million and net income of US$456 million on August 6, while also completing a US$439.14 million share repurchase program that covered 20,387,000...","category":"company","datetime":1787235222,"headline":"Kenvue (KVUE) Launches Zyrtec Spray As Its Undervalued Case Faces A Fresh Test"}
raw_source {"id":142166644,"url":"https://finnhub.io/api/news?id=0584841adf1dbf70c8f50793d7796a06d8f19910a7ddba0df8f06a55f988dae6","image":"https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp","source":"ChartMill","related":"KVUE","summary":"Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Tuesday and uncover the stocks that are leading the way in terms of trading volume and market attention.","category":"company","datetime":1789495500,"headline":"Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session."}, {"id":142166216,"url":"https://finnhub.io/api/news?id=0b01c4efa9a88f652753ccd0bb270fdd7f39647ec9bffff2d7f3f3f8dbbb41e4","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Kenvue Inc. previously announced that its Board of Directors declared a quarterly dividend of US$0.21 per share, payable on October 2, 2026, to shareholders of record as of September 21, 2026, while also securing FDA approval for TYLENOL with Naproxen, a first-of-its-kind non-opioid OTC pain reliever backed by multiple clinical studies. By pairing a new, clinically supported TYLENOL with Naproxen launch with ongoing cash returns via dividends, Kenvue is highlighting both product innovation...","category":"company","datetime":1789492334,"headline":"Should Kenvue’s (KVUE) TYLENOL with Naproxen Launch and Dividend Plan Prompt Investor Reassessment?"}, {"id":142166217,"url":"https://finnhub.io/api/news?id=6001775f3a84f88a94e43e27d5847522896be1df7e3e8fa648fd7f246df94a34","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Kenvue (KVUE) is on investors’ radar after launching TYLENOL with Naproxen, an FDA-approved, opioid-free over the counter pain reliever that combines acetaminophen and naproxen sodium, backed by extensive clinical research. That launch comes as Kenvue’s share price has softened in the short term, with a 7 day share price return of down 4.43% and a 30 day share price return of down 6.72%. Even though the year to date share price return is 3.41% and the 1 year total shareholder return is 2.85%,...","category":"company","datetime":1789485377,"headline":"Is Kenvue (KVUE) A Bargain Following Its TYLENOL With Naproxen Launch?"}, {"id":142166218,"url":"https://finnhub.io/api/news?id=24903ebd70f8d89708c3a732ceb6c2c4d836ac083f4e880f8e44baf53ed6cf92","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Kimberly-Clark Corporation (NASDAQ:KMB) is preparing asset sales to address EU antitrust concerns surrounding its planned $40 billion acquisition of Kenvue, according to Reuters. The company is reportedly seeking to offer remedies that could secure European Commission approval by the September 29 deadline, avoiding a more extensive four-month investigation. Similar regulatory concerns have already emerged in […]","category":"company","datetime":1789482726,"headline":"Kimberly-Clark Moves to Clear EU Hurdle with Kenvue Asset Sales"}, {"id":142141334,"url":"https://finnhub.io/api/news?id=e8c556cb9ce88ebb8900d9fa386b67120a0bebc54510b6d3c24431c426593ed8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Consumer stocks were mixed late Monday afternoon, with the State Street Consumer Staples Select Sect","category":"company","datetime":1789415435,"headline":"Sector Update: Consumer Stocks Mixed Late Afternoon"}, {"id":142139935,"url":"https://finnhub.io/api/news?id=b2261b4dc5b59c3755bfea444dc6f7112e692fae63d3f795e7b1e23428244bca","image":"https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp","source":"ChartMill","related":"KVUE","summary":"Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Monday. Discover the stocks that are generating the highest trading volume and driving market activity.","category":"company","datetime":1789409101,"headline":"These S&P500 stocks are the most active in today's session"}, {"id":142139269,"url":"https://finnhub.io/api/news?id=f831f32d0eec410e942e8e5956128a9b6a670f8821119d305230199e0b205417","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Kenvue's dependable dividend is above average, and it could go even higher if the company is bought by Kimberly-Clark.","category":"company","datetime":1789401000,"headline":"Here's My Pick for the Smartest High-Yield Dividend Stock to Buy Right Now"}, {"id":142137340,"url":"https://finnhub.io/api/news?id=f160bd34be65c873f0603038255240340cffd170cd831f7c96fb72fe882e6308","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Colgate is reportedly shopping Softsoap, Irish Spring, and Speed Stick with Goldman Sachs running the process, but the names most investors would expect to step up all have reasons to sit this one out.","category":"company","datetime":1789391416,"headline":"Who Buys Colgate’s Cast-Off Brands? Why the Obvious Answers Are Unlikely."}, {"id":142128446,"url":"https://finnhub.io/api/news?id=651996f1c12f137e65bb2e78fe3b3305b9ad922bb726611e70fd3fb0f5eed008","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Sorbent Paper Company Pty Ltd (\"Sorbent\") has signed an agreement with Kenvue's Singaporean subsidiary to acquire its Stayfree and Carefree feminine care business in Australia and New Zealand. Following completion of the transaction, the business in New Zealand will be managed by Sorbent's affiliate, Cottonsoft.","category":"company","datetime":1789358280,"headline":"Sorbent to acquire Kenvue's Stayfree and Carefree business in Australia and New Zealand"}, {"id":142118127,"url":"https://finnhub.io/api/news?id=d20316c920b861501286233423fcf2b20ebfa6c6fa16ae3aecae845c4b1d0799","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Kenvue stock has lagged the broader market over the past year, although analysts remain neutral on the company’s future prospects.","category":"company","datetime":1789235844,"headline":"Is Kenvue Underperforming the Nasdaq?"}, {"id":142115646,"url":"https://finnhub.io/api/news?id=e166f924385033dde1b4208f0985a308d168ffcd80e369340966a39497b32cf4","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Kimberly-Clark just raised its dividend for the 54th straight year while simultaneously chasing a nearly $50 billion acquisition, and income investors are now weighing whether a deal of that size can coexist with a payout that costs over $1.6 billion annually.","category":"company","datetime":1789235351,"headline":"Kimberly-Clark’s 54-Year Dividend Streak Faces Its Biggest Test Yet With $48.7 Billion Kenvue Deal"}, {"id":142088574,"url":"https://finnhub.io/api/news?id=b1bf5bf7a8d8db24bb8397bc49b2a54acd3696ad4f4a84caf8c60fbaa16ce6cf","image":"https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp","source":"ChartMill","related":"KVUE","summary":"Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.","category":"company","datetime":1789149902,"headline":"Curious about the most active S&P500 stocks in today's session?"}, {"id":142087796,"url":"https://finnhub.io/api/news?id=4f5b7ad0d84ef575a60333272561a407ccd143683a9274507366309e49313ee9","image":"https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp","source":"ChartMill","related":"KVUE","summary":"Let's have a look at the S&P500 stocks with an unusual volume in today's session.","category":"company","datetime":1789146300,"headline":"In today's session, there are S&P500 stocks with remarkable trading volume."}, {"id":142057291,"url":"https://finnhub.io/api/news?id=d40d0c2965dc934870fd4f5b8d5ad107a060f7d6c4c95ae28992107a1669a064","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"SUMMIT, N.J., September 10, 2026--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.21 per share on its common stock. The quarterly dividend is payable on October 2, 2026, to shareholders of record as of the close of business on September 21, 2026.","category":"company","datetime":1789037100,"headline":"Kenvue Declares Quarterly Cash Dividend"}, {"id":142025638,"url":"https://finnhub.io/api/news?id=de527c4017ba098f6eddbb8037d3d85d0ebe5f38f4beb47c5dcb23bcd820f5b4","image":"","source":"Benzinga","related":"KVUE","summary":"https://www.reuters.com/business/healthcare-pharmaceuticals/tylenol-use-pregnancy-may-be-linked-with-uterus-ovary-changes-daughters-2026-09-09/","category":"company","datetime":1788947467,"headline":"Reported September 8, 2026: 'Tylenol Use In Pregnancy May Be Linked With Uterus, Ovary Changes In Daughters' - Reuters News"}, {"id":141951170,"url":"https://finnhub.io/api/news?id=75fead89f45544c493496f3562cafd83f45c34472705a519771300549f4e4def","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"KVUE's trusted brands, innovation and productivity initiatives support growth as it strengthens its consumer health portfolio and global reach.","category":"company","datetime":1788878820,"headline":"Kenvue's Brand Strength and Innovation Strategy Support Growth"}, {"id":141949289,"url":"https://finnhub.io/api/news?id=4d692700574c5bd991de1cb46707cbbc7162de9134cc7fb87a13d812a326409e","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2182047027/image_2182047027.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"KVUE","summary":"Key contributors include Infineon Technologies, Teradyne and Walmart. Learn more about key detractors.","category":"company","datetime":1788861600,"headline":"American Century Value Fund Q2 2026 Contributors And Detractors"}, {"id":141772565,"url":"https://finnhub.io/api/news?id=5e844c2d43a8aa6c28d198fd925d3f2c06c12c9621142c58f8c7b2480fe32ab7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Kimberly-Clark Corporation’s (NASDAQ:KMB) proposed $40 billion takeover of Kenvue has entered another stage of regulatory review. Documents on the European Commission’s website show that Kimberly-Clark has requested EU permission to complete the transaction, which was first announced in November 2025. The deal would combine Kimberly-Clark (NASDAQ:KMB) with a large portfolio of consumer-health brands, including Tylenol, […]","category":"company","datetime":1788829402,"headline":"Can Kimberly-Clark Turn its $40 Billion Kenvue Bet into $2.1 Billion in Savings?"}, {"id":141771434,"url":"https://finnhub.io/api/news?id=aa27da536d50efd6679bcfd77d715631ee64f99862603b3e3817532e17f0638d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"KVUE nears its planned combination after shareholder and U.S. antitrust clearances, while margin, debt and legal risks temper the Q4 2026 outlook.","category":"company","datetime":1788809280,"headline":"Kenvue's Kimberly-Clark Deal Nears Closing With Key Risks Still Ahead"}, {"id":141771435,"url":"https://finnhub.io/api/news?id=c7fb779f54328c36dd6407d82131e651780d8d24dbeab0820fdfc8bbec803f7b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Kenvue's profit margins and cash flow improved in the first half, but modest sales growth, debt and uneven segment trends keep the risk-reward balanced.","category":"company","datetime":1788809160,"headline":"Should Investors Buy KVUE as Margin Gains Offset Slow Sales Growth?"}, {"id":141364398,"url":"https://finnhub.io/api/news?id=09d17b13a3b9623d1cbaf1c6affe0168839e4c7814c7d78cf92b2d3e5cbbcdb8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Deal skepticism and litigation fears still weigh on this consumer staples stalwart.","category":"company","datetime":1788186900,"headline":"This Dividend King Just Offered a Buy-the-Dip Opportunity"}, {"id":141336283,"url":"https://finnhub.io/api/news?id=d92db7b94ab38deb8d45bd11ce337de7df789b48d477823807203626cf4038b8","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215519735/image_2215519735.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"KVUE","summary":"Dividend Aristocrats (NOBL) nearly match SPY in 2026, with top gainers, rising dividend growth, and 29 undervalued picks—see which to buy now.","category":"company","datetime":1787894920,"headline":"Best Dividend Aristocrats For September 2026"}, {"id":141364399,"url":"https://finnhub.io/api/news?id=0cdf3bbf82fd4d3692b991366108d2d79958c3da74c34e9b945ade1fee13dd52","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Kimberly-Clark (KMB) stock is in focus after the company named Suzana Blades as Senior Vice President and General Counsel, with a future role tied to its pending acquisition of Kenvue Inc. Kimberly-Clark shares trade at US$110.34, with the stock up 10.2% over the past 90 days and 8.8% year to date on a share price basis, even though the 1 year total shareholder return has declined 11.1%. This points to improving short term momentum alongside a weaker longer term experience for...","category":"company","datetime":1787846798,"headline":"Kimberly Clark (KMB) Names New Legal Chief As Kenvue Deal Puts Valuation In Focus"}, {"id":141364401,"url":"https://finnhub.io/api/news?id=7d1eb0210e7bb49c050819cf974eab94fa77135ae900c69af885597380b1861d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Pure Strategies, a sustainability consulting firm empowering brands and retailers to realize meaningful environmental and social improvement, is offering a full day of workshops, panels, and small group discussions during Climate Week NYC. The \"Day of Action\" program, being held Wednesday, September 23, 2026, is designed to help companies advance climate and nature strategies and turn sustainability investment into measurable returns.","category":"company","datetime":1787775420,"headline":"Pure Strategies Announces \"Day of Action\" Full Day Program during Climate Week NYC - September 23, 2026"}, {"id":141324202,"url":"https://finnhub.io/api/news?id=c710f4da94ba6b1816de5555e8b2151446aae51f52ce20fa254d5a2921bdc8fd","image":"https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp","source":"ChartMill","related":"KVUE","summary":"Stay informed about the most active stocks in the S&P500 index on Wednesday's session. Discover the stocks that are generating the highest trading volume and driving market activity.","category":"company","datetime":1787767501,"headline":"Explore the S&P500 index on Wednesday and find out which stocks are the most active in today's session."}, {"id":141312616,"url":"https://finnhub.io/api/news?id=041f861e37772b1094116dba0988f23039993625d6d2ef845d0a2ee0d16a1e4d","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/458559027/image_458559027.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"KVUE","summary":"Kenvue Inc. upgraded to a soft buy as the Kimberly-Clark Corporation merger looks likely. Click for this updated look at KVUE and KMB as they seek to join.","category":"company","datetime":1787599909,"headline":"Kenvue Deserves Some Love As Its Purchase By Kimberly-Clark Looks Imminent"}, {"id":141364400,"url":"https://finnhub.io/api/news?id=f57b06989658200ab5d2eae0097a7252b38920e5534a9d42d5ec6e6a1c7b2034","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"In a challenge brought by Kenvue Inc., BBB National Programs’ National Advertising Division determined that Hims & Hers Health, Inc. provided a reasonable basis for its comparative efficacy claim. However, the National Advertising Division (NAD) recommended that it modify or discontinue other claims regarding doctor-trusted ingredients, dermatologist recommendations, safety and side effects.New York, NY, Aug. 24, 2026 (GLOBE NEWSWIRE) -- In a challenge brought by Kenvue Inc., BBB National Progra","category":"company","datetime":1787594400,"headline":"National Advertising Division Finds Hims & Hers Has Support for Combination Efficacy Message; Recommends Modification or Discontinuance of Other Claims"}, {"id":141310775,"url":"https://finnhub.io/api/news?id=8ebad401400c6591cbad60ecd91bb62c4623c346f30482ec02166fddb02adf4f","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2257340277/image_2257340277.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"KVUE","summary":"Kenvue Inc.’s KMB buyout faces China SAMR Phase 2 antitrust review. Click for more on KVUE and how this affects whether you should invest in KVUE stock.","category":"company","datetime":1787586192,"headline":"Kenvue: Acquisition By Kimberly-Clark Hit An Obstacle - What Now"}, {"id":141364402,"url":"https://finnhub.io/api/news?id=730a9ed2aaaaa65bb9c2e979496358c87934786262e81db479e74c94f7a9899f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"The beauty group's repricing rests on a profit plan it controls, while the low end of its new sales guidance is no faster than the year just ended.","category":"company","datetime":1787585240,"headline":"Estee Lauder Stock Jumped On A Bigger Margin Promise"}, {"id":141307500,"url":"https://finnhub.io/api/news?id=32b08bbe296e7cb212fd1ae7c5aebca8ee10a12f8968f1cb43ac3b54896393a6","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2260312486/image_2260312486.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"KVUE","summary":"Dividend Kings beat the S&P 500 YTD, with 30 topping SPY and 25 looking undervalued with 10%+ return potential.","category":"company","datetime":1787547151,"headline":"Best Dividend Kings: August 2026"}, {"id":141282754,"url":"https://finnhub.io/api/news?id=d6e8702ffd287b3173c9163b137bb8ec42a1739ff848e40850de334af327d7ca","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Kenvue stock has delivered a 9.3% gain year to date. Its current share price of US$18.93 still sits well below an intrinsic value estimate from a Discounted Cash Flow (DCF) model, which points to a 36.4% discount. At the same time, traditional earnings multiples suggest the shares look about fairly priced, leaving investors weighing a clear DCF upside signal against more neutral market ratios. Year to date, Kenvue is up 9.3%, indicating the market has already repriced the stock higher even...","category":"company","datetime":1787292615,"headline":"Kenvue (KVUE) Stock Looks Cheap On Cash Flow But Fair On Earnings"}, {"id":141282755,"url":"https://finnhub.io/api/news?id=a45b9ab18c80eae5ef52d4897040a916581758913448bcfaed72ddb23667f08f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"In August 2026, Kenvue’s Zyrtec brand launched Zyrtec Allergen Shield Spray, a drug-free nasal mist that forms a gel barrier in the nose within minutes to help block common airborne allergens like pollen, pet dander, and dust for up to six hours in adults and children aged 12 and older. This first-of-its-kind, HPMC-based spray expands Zyrtec’s toolkit toward proactive allergen defense, signaling Kenvue’s push into drug-free, preventative allergy solutions. We’ll now examine how this new...","category":"company","datetime":1787271185,"headline":"Should Zyrtec’s New Drug-Free Allergen Shield Spray Launch Require Action From Kenvue (KVUE) Investors?"}, {"id":141278128,"url":"https://finnhub.io/api/news?id=6ae953c0c2a0889b6642fd3164e527ee58f54d9cc09703b5237c69b976de98ca","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Johnson & Johnson's new drugs may offset declining sales due to patent-protection losses.","category":"company","datetime":1787242320,"headline":"Johnson & Johnson Just Sent Shareholders an Important 11-Word Message About Its Future"}, {"id":141282763,"url":"https://finnhub.io/api/news?id=adbbcf502704dea0876fa7d6c12f56918adec15fb19170df8f68192c3d1726d1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Panettiere's death has re-ignited calls to boycott Neutrogena, which she said ended a partnership after she spoke out about postpartum depression.","category":"company","datetime":1787239528,"headline":"Will a Neutrogena boycott by Hayden Panettiere's fans work?"}, {"id":141282756,"url":"https://finnhub.io/api/news?id=f7e9f9af2724ae75a24bbee4208fcfc80ce1a514f2e2f949f1a3e6ffa79e11d9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Zyrtec Allergen Shield Spray, a new drug free nasal mist from Kenvue (KVUE), has given investors fresh product news to weigh. The launch highlights activity in the company’s Self Care allergy portfolio. See our latest analysis for Kenvue. The recent Zyrtec Allergen Shield Spray launch comes after Kenvue reported second quarter 2026 sales of US$3,955 million and net income of US$456 million on August 6, while also completing a US$439.14 million share repurchase program that covered 20,387,000...","category":"company","datetime":1787235222,"headline":"Kenvue (KVUE) Launches Zyrtec Spray As Its Undervalued Case Faces A Fresh Test"}, {"id":141282767,"url":"https://finnhub.io/api/news?id=059ca06eb53a909a27ad9eb14e946821ac0e6d252bd14713a5cb17ac4352d1be","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"KVUE","summary":"Hygiene and health company Essity has entered into an agreement to acquire Kenvue's feminine care business in Brazil, including the market-leading brands Carefree, Sempre Livre and o.b. The purchase price amounts to USD 284m (approximately SEK 2.7bn) on a cash and debt-free basis. The acquisition strengthens Essity's position as a market leader in feminine care in Latin America.","category":"company","datetime":1787198760,"headline":"Essity acquires feminine care business in Brazil"}, {"id":141261729,"url":"https://finnhub.io/api/news?id=c88cc7e7cc91f6d0020d7de624a2c351fd92acbfd3808ec26302e04d766c0a55","image":"","source":"Benzinga","related":"KVUE","summary":"https://www.essity.com/media/press-release/essity-acquires-feminine-care-business-in-brazil/9dd724cebbb532f5/","category":"company","datetime":1787144784,"headline":"Essity Strikes Agreement To Acquire Kenvue's Feminine Care Operations In Brazil For $284M"}
data_source finnhub_news_keyword_model
article_count 6
negative_hits 0
positive_hits 2
recomputed_at_score true
sentiment_score_raw 0.8
source_article_count 37
discarded_article_count 31
sentimentPoints 4

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 4.1 5/110 82% 4.1
資金流 8.4 20/110 42% 8.4
市場環境 5.6 15/110 37.33% 5.6
催化劑 2 20/110 10% 2
風險管理 7.6 10/110 76% 7.6
技術信號 12.6 30/110 42% 12.6
情緒分析 4 10/110 40% 4

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 11/50
ret_5d -0.0256
max_score 50
max_total 50
raw_total 11
vcp_bonus 0
vol_ratio 2.0848
ret_points 0
vol_points 8
range_ratio 0.7813
volat_points 0
day_range_pct 0.0131
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 3
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Medium
reason risk management score >= 6.5/10

position

score 1.8

details

atrPct 1.9018
turnoverUsdM 964.5333
liquidityPoints 0.6
volatilityPoints 1.2
rrPoints 1.4

stopLevels

symbol US.KVUE
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 17.2384

strength_details

ma_score 1
atr_score 2.5
rsi_score 2.5
macd_score 1
volume_score 2
market_adjustment 1
risk_reward_ratio 1.3
stop_loss_percent 3.8
take_profit_price 18.816
target_multiplier 1.9
technical_strength 1.73
take_profit_percent 5
positionPoints 1.8
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Consumer Staples
concentratedSectorPenalty 0
riskRewardRatio 1.3146
stopLossPercent 3.8036
diversificationPoints 2

Calculation audit log

基本面分析總分: 4.1/5分
資金流分析總分: 8.4/20分
市場環境分析總分: 5.6/15分
催化劑分析: 2/20分
風險管理總分: 7.6/10分
技術信號分析總分: 12.6/30分
情緒分析: 4/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 92.86
atr
atr 0.3408
rule ATR / current price; lower volatility scores higher
score 8
atr_pct 1.9
cci
rule Cursor_18.24 CCI bands
level 超買或超賣風險
score 2
value -127.52
cmf
rule Cursor_18.24 CMF bands
level 派發
score 2
value -0.1613
kdj
d 15.53
j 16.68
k 15.91
rule Cursor_18.24 K/D cross
score 4
signal 金叉
mfi
rule Cursor_18.24 MFI bands
level 超賣或超買風險
score 2
value 24.1
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 10
trend 強流入
value 47308502
recentSlope 4525660.2
previousSlope -7311400
rsi
value 22.13
sar
rule Cursor_18.24 Parabolic SAR
score 4
trend 下降
value 18.5068
position SAR喺價上
distancePct 3.27
previousTrend 下降
ma50
value 19.0096
macd
macd -0.3269
trend 看跌
signal -0.2019
histogram -0.125
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 2
value 18.5222
position <VWAP
consecutiveAbove 0
volume
rule Cursor_18.24 volume ratio
level 有量
ratio 1.99
score 6
avgVolume 27110310
currentVolume 53824402
derived
ma20 18.713
ma50 19.0096
prevClose 17.91
avgVolume10 33359750
avgVolume20 27110310
changePercent 0.06
avgVolumeForScore 27110310
ma_cross
ma20 18.713
ma50 19.0096
rule Cursor_18.24 MA20/MA50 cross
cross 熊勢
score 0
prevMa20 18.7565
prevMa50 19.0424
spreadPct 1.56
isVolumeBreakout true
bollinger
lower 17.5963
upper 19.8297
position 中間
rsi_short
value 15.25
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 1.99

Raw calculation JSON

 
{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.8,
      "details": {
        "atrPct": 1.9017857142857142,
        "turnoverUsdM": 964.5332838400001,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1.2
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.KVUE",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 17.2384,
      "strength_details": {
        "ma_score": 1,
        "atr_score": 2.5,
        "rsi_score": 2.5,
        "macd_score": 1,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.3,
      "stop_loss_percent": 3.8,
      "take_profit_price": 18.816,
      "target_multiplier": 1.9,
      "technical_strength": 1.73,
      "take_profit_percent": 5
    },
    "positionPoints": 1.8,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Consumer Staples",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.3145539906103287,
    "stopLossPercent": 3.8035714285714284,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 55.3,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 44.3,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 11
  },
  "market": {
    "ma20": 18.713,
    "ma50": 19.0096,
    "close": 17.92,
    "prevClose": 17.91,
    "avgVolume20": 27110310,
    "volumeRatio": 1.99,
    "changePercent": 0.06
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 11,
    "details": {
      "ret_5d": -0.025557368134855873,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 11,
      "vcp_bonus": 0,
      "vol_ratio": 2.0847969648582407,
      "ret_points": 0,
      "vol_points": 8,
      "range_ratio": 0.7813208782983764,
      "volat_points": 0,
      "day_range_pct": 0.013147321428571515,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 55.3,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4.1,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 82,
        "contribution": 4.1
      },
      {
        "raw": 8.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 42,
        "contribution": 8.4
      },
      {
        "raw": 5.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 37.33,
        "contribution": 5.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.6,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 76,
        "contribution": 7.6
      },
      {
        "raw": 12.6,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 42,
        "contribution": 12.6
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 44.3,
    "details": [
      "基本面分析總分: 4.1/5分",
      "資金流分析總分: 8.4/20分",
      "市場環境分析總分: 5.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.6/10分",
      "技術信號分析總分: 12.6/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 4.1,
      "資金流": 8.4,
      "市場環境": 5.6,
      "情緒分析": 4,
      "技術信號": 12.6,
      "風險管理": 7.6
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 6,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.4,
          "pePoints": 0.4,
          "epsPoints": 0.75,
          "roePoints": 0.6,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 964.5332838400001,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.5,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 0.8,
          "obvPoints": 4,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.KVUE",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 713.30699735,
                "ma50": 709.9723986999998,
                "name": "QQQ",
                "close": 704.53998,
                "points": 0.4
              },
              "spy": {
                "ma20": 765.34199445,
                "ma50": 759.0606000200002,
                "name": "SPY",
                "close": 757.39001,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 1.9017857142857142,
          "atrPoints": 4,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 6,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.8
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142166216,
                "url": "https://finnhub.io/api/news?id=0b01c4efa9a88f652753ccd0bb270fdd7f39647ec9bffff2d7f3f3f8dbbb41e4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue Inc. previously announced that its Board of Directors declared a quarterly dividend of US$0.21 per share, payable on October 2, 2026, to shareholders of record as of September 21, 2026, while also securing FDA approval for TYLENOL with Naproxen, a first-of-its-kind non-opioid OTC pain reliever backed by multiple clinical studies. By pairing a new, clinically supported TYLENOL with Naproxen launch with ongoing cash returns via dividends, Kenvue is highlighting both product innovation...",
                "category": "company",
                "datetime": 1789492334,
                "headline": "Should Kenvue’s (KVUE) TYLENOL with Naproxen Launch and Dividend Plan Prompt Investor Reassessment?"
              },
              {
                "id": 142166217,
                "url": "https://finnhub.io/api/news?id=6001775f3a84f88a94e43e27d5847522896be1df7e3e8fa648fd7f246df94a34",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue (KVUE) is on investors’ radar after launching TYLENOL with Naproxen, an FDA-approved, opioid-free over the counter pain reliever that combines acetaminophen and naproxen sodium, backed by extensive clinical research. That launch comes as Kenvue’s share price has softened in the short term, with a 7 day share price return of down 4.43% and a 30 day share price return of down 6.72%. Even though the year to date share price return is 3.41% and the 1 year total shareholder return is 2.85%,...",
                "category": "company",
                "datetime": 1789485377,
                "headline": "Is Kenvue (KVUE) A Bargain Following Its TYLENOL With Naproxen Launch?"
              },
              {
                "id": 141771435,
                "url": "https://finnhub.io/api/news?id=c7fb779f54328c36dd6407d82131e651780d8d24dbeab0820fdfc8bbec803f7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue's profit margins and cash flow improved in the first half, but modest sales growth, debt and uneven segment trends keep the risk-reward balanced.",
                "category": "company",
                "datetime": 1788809160,
                "headline": "Should Investors Buy KVUE as Margin Gains Offset Slow Sales Growth?"
              },
              {
                "id": 141282754,
                "url": "https://finnhub.io/api/news?id=d6e8702ffd287b3173c9163b137bb8ec42a1739ff848e40850de334af327d7ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue stock has delivered a 9.3% gain year to date. Its current share price of US$18.93 still sits well below an intrinsic value estimate from a Discounted Cash Flow (DCF) model, which points to a 36.4% discount. At the same time, traditional earnings multiples suggest the shares look about fairly priced, leaving investors weighing a clear DCF upside signal against more neutral market ratios. Year to date, Kenvue is up 9.3%, indicating the market has already repriced the stock higher even...",
                "category": "company",
                "datetime": 1787292615,
                "headline": "Kenvue (KVUE) Stock Looks Cheap On Cash Flow But Fair On Earnings"
              },
              {
                "id": 141282755,
                "url": "https://finnhub.io/api/news?id=a45b9ab18c80eae5ef52d4897040a916581758913448bcfaed72ddb23667f08f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "In August 2026, Kenvue’s Zyrtec brand launched Zyrtec Allergen Shield Spray, a drug-free nasal mist that forms a gel barrier in the nose within minutes to help block common airborne allergens like pollen, pet dander, and dust for up to six hours in adults and children aged 12 and older. This first-of-its-kind, HPMC-based spray expands Zyrtec’s toolkit toward proactive allergen defense, signaling Kenvue’s push into drug-free, preventative allergy solutions. We’ll now examine how this new...",
                "category": "company",
                "datetime": 1787271185,
                "headline": "Should Zyrtec’s New Drug-Free Allergen Shield Spray Launch Require Action From Kenvue (KVUE) Investors?"
              },
              {
                "id": 141282756,
                "url": "https://finnhub.io/api/news?id=f7e9f9af2724ae75a24bbee4208fcfc80ce1a514f2e2f949f1a3e6ffa79e11d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Zyrtec Allergen Shield Spray, a new drug free nasal mist from Kenvue (KVUE), has given investors fresh product news to weigh. The launch highlights activity in the company’s Self Care allergy portfolio. See our latest analysis for Kenvue. The recent Zyrtec Allergen Shield Spray launch comes after Kenvue reported second quarter 2026 sales of US$3,955 million and net income of US$456 million on August 6, while also completing a US$439.14 million share repurchase program that covered 20,387,000...",
                "category": "company",
                "datetime": 1787235222,
                "headline": "Kenvue (KVUE) Launches Zyrtec Spray As Its Undervalued Case Faces A Fresh Test"
              }
            ],
            "raw_source": [
              {
                "id": 142166644,
                "url": "https://finnhub.io/api/news?id=0584841adf1dbf70c8f50793d7796a06d8f19910a7ddba0df8f06a55f988dae6",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "KVUE",
                "summary": "Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Tuesday and uncover the stocks that are leading the way in terms of trading volume and market attention.",
                "category": "company",
                "datetime": 1789495500,
                "headline": "Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session."
              },
              {
                "id": 142166216,
                "url": "https://finnhub.io/api/news?id=0b01c4efa9a88f652753ccd0bb270fdd7f39647ec9bffff2d7f3f3f8dbbb41e4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue Inc. previously announced that its Board of Directors declared a quarterly dividend of US$0.21 per share, payable on October 2, 2026, to shareholders of record as of September 21, 2026, while also securing FDA approval for TYLENOL with Naproxen, a first-of-its-kind non-opioid OTC pain reliever backed by multiple clinical studies. By pairing a new, clinically supported TYLENOL with Naproxen launch with ongoing cash returns via dividends, Kenvue is highlighting both product innovation...",
                "category": "company",
                "datetime": 1789492334,
                "headline": "Should Kenvue’s (KVUE) TYLENOL with Naproxen Launch and Dividend Plan Prompt Investor Reassessment?"
              },
              {
                "id": 142166217,
                "url": "https://finnhub.io/api/news?id=6001775f3a84f88a94e43e27d5847522896be1df7e3e8fa648fd7f246df94a34",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue (KVUE) is on investors’ radar after launching TYLENOL with Naproxen, an FDA-approved, opioid-free over the counter pain reliever that combines acetaminophen and naproxen sodium, backed by extensive clinical research. That launch comes as Kenvue’s share price has softened in the short term, with a 7 day share price return of down 4.43% and a 30 day share price return of down 6.72%. Even though the year to date share price return is 3.41% and the 1 year total shareholder return is 2.85%,...",
                "category": "company",
                "datetime": 1789485377,
                "headline": "Is Kenvue (KVUE) A Bargain Following Its TYLENOL With Naproxen Launch?"
              },
              {
                "id": 142166218,
                "url": "https://finnhub.io/api/news?id=24903ebd70f8d89708c3a732ceb6c2c4d836ac083f4e880f8e44baf53ed6cf92",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kimberly-Clark Corporation (NASDAQ:KMB) is preparing asset sales to address EU antitrust concerns surrounding its planned $40 billion acquisition of Kenvue, according to Reuters. The company is reportedly seeking to offer remedies that could secure European Commission approval by the September 29 deadline, avoiding a more extensive four-month investigation. Similar regulatory concerns have already emerged in […]",
                "category": "company",
                "datetime": 1789482726,
                "headline": "Kimberly-Clark Moves to Clear EU Hurdle with Kenvue Asset Sales"
              },
              {
                "id": 142141334,
                "url": "https://finnhub.io/api/news?id=e8c556cb9ce88ebb8900d9fa386b67120a0bebc54510b6d3c24431c426593ed8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Consumer stocks were mixed late Monday afternoon, with the State Street Consumer Staples Select Sect",
                "category": "company",
                "datetime": 1789415435,
                "headline": "Sector Update: Consumer Stocks Mixed Late Afternoon"
              },
              {
                "id": 142139935,
                "url": "https://finnhub.io/api/news?id=b2261b4dc5b59c3755bfea444dc6f7112e692fae63d3f795e7b1e23428244bca",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "KVUE",
                "summary": "Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Monday. Discover the stocks that are generating the highest trading volume and driving market activity.",
                "category": "company",
                "datetime": 1789409101,
                "headline": "These S&P500 stocks are the most active in today's session"
              },
              {
                "id": 142139269,
                "url": "https://finnhub.io/api/news?id=f831f32d0eec410e942e8e5956128a9b6a670f8821119d305230199e0b205417",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue's dependable dividend is above average, and it could go even higher if the company is bought by Kimberly-Clark.",
                "category": "company",
                "datetime": 1789401000,
                "headline": "Here's My Pick for the Smartest High-Yield Dividend Stock to Buy Right Now"
              },
              {
                "id": 142137340,
                "url": "https://finnhub.io/api/news?id=f160bd34be65c873f0603038255240340cffd170cd831f7c96fb72fe882e6308",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Colgate is reportedly shopping Softsoap, Irish Spring, and Speed Stick with Goldman Sachs running the process, but the names most investors would expect to step up all have reasons to sit this one out.",
                "category": "company",
                "datetime": 1789391416,
                "headline": "Who Buys Colgate’s Cast-Off Brands? Why the Obvious Answers Are Unlikely."
              },
              {
                "id": 142128446,
                "url": "https://finnhub.io/api/news?id=651996f1c12f137e65bb2e78fe3b3305b9ad922bb726611e70fd3fb0f5eed008",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Sorbent Paper Company Pty Ltd (\"Sorbent\") has signed an agreement with Kenvue's Singaporean subsidiary to acquire its Stayfree and Carefree feminine care business in Australia and New Zealand. Following completion of the transaction, the business in New Zealand will be managed by Sorbent's affiliate, Cottonsoft.",
                "category": "company",
                "datetime": 1789358280,
                "headline": "Sorbent to acquire Kenvue's Stayfree and Carefree business in Australia and New Zealand"
              },
              {
                "id": 142118127,
                "url": "https://finnhub.io/api/news?id=d20316c920b861501286233423fcf2b20ebfa6c6fa16ae3aecae845c4b1d0799",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue stock has lagged the broader market over the past year, although analysts remain neutral on the company’s future prospects.",
                "category": "company",
                "datetime": 1789235844,
                "headline": "Is Kenvue Underperforming the Nasdaq?"
              },
              {
                "id": 142115646,
                "url": "https://finnhub.io/api/news?id=e166f924385033dde1b4208f0985a308d168ffcd80e369340966a39497b32cf4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kimberly-Clark just raised its dividend for the 54th straight year while simultaneously chasing a nearly $50 billion acquisition, and income investors are now weighing whether a deal of that size can coexist with a payout that costs over $1.6 billion annually.",
                "category": "company",
                "datetime": 1789235351,
                "headline": "Kimberly-Clark’s 54-Year Dividend Streak Faces Its Biggest Test Yet With $48.7 Billion Kenvue Deal"
              },
              {
                "id": 142088574,
                "url": "https://finnhub.io/api/news?id=b1bf5bf7a8d8db24bb8397bc49b2a54acd3696ad4f4a84caf8c60fbaa16ce6cf",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "KVUE",
                "summary": "Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.",
                "category": "company",
                "datetime": 1789149902,
                "headline": "Curious about the most active S&P500 stocks in today's session?"
              },
              {
                "id": 142087796,
                "url": "https://finnhub.io/api/news?id=4f5b7ad0d84ef575a60333272561a407ccd143683a9274507366309e49313ee9",
                "image": "https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp",
                "source": "ChartMill",
                "related": "KVUE",
                "summary": "Let's have a look at the S&P500 stocks with an unusual volume in today's session.",
                "category": "company",
                "datetime": 1789146300,
                "headline": "In today's session, there are S&P500 stocks with remarkable trading volume."
              },
              {
                "id": 142057291,
                "url": "https://finnhub.io/api/news?id=d40d0c2965dc934870fd4f5b8d5ad107a060f7d6c4c95ae28992107a1669a064",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "SUMMIT, N.J., September 10, 2026--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.21 per share on its common stock. The quarterly dividend is payable on October 2, 2026, to shareholders of record as of the close of business on September 21, 2026.",
                "category": "company",
                "datetime": 1789037100,
                "headline": "Kenvue Declares Quarterly Cash Dividend"
              },
              {
                "id": 142025638,
                "url": "https://finnhub.io/api/news?id=de527c4017ba098f6eddbb8037d3d85d0ebe5f38f4beb47c5dcb23bcd820f5b4",
                "image": "",
                "source": "Benzinga",
                "related": "KVUE",
                "summary": "https://www.reuters.com/business/healthcare-pharmaceuticals/tylenol-use-pregnancy-may-be-linked-with-uterus-ovary-changes-daughters-2026-09-09/",
                "category": "company",
                "datetime": 1788947467,
                "headline": "Reported September 8, 2026: 'Tylenol Use In Pregnancy May Be Linked With Uterus, Ovary Changes In Daughters' - Reuters News"
              },
              {
                "id": 141951170,
                "url": "https://finnhub.io/api/news?id=75fead89f45544c493496f3562cafd83f45c34472705a519771300549f4e4def",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "KVUE's trusted brands, innovation and productivity initiatives support growth as it strengthens its consumer health portfolio and global reach.",
                "category": "company",
                "datetime": 1788878820,
                "headline": "Kenvue's Brand Strength and Innovation Strategy Support Growth"
              },
              {
                "id": 141949289,
                "url": "https://finnhub.io/api/news?id=4d692700574c5bd991de1cb46707cbbc7162de9134cc7fb87a13d812a326409e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2182047027/image_2182047027.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "KVUE",
                "summary": "Key contributors include Infineon Technologies, Teradyne and Walmart. Learn more about key detractors.",
                "category": "company",
                "datetime": 1788861600,
                "headline": "American Century Value Fund Q2 2026 Contributors And Detractors"
              },
              {
                "id": 141772565,
                "url": "https://finnhub.io/api/news?id=5e844c2d43a8aa6c28d198fd925d3f2c06c12c9621142c58f8c7b2480fe32ab7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kimberly-Clark Corporation’s (NASDAQ:KMB) proposed $40 billion takeover of Kenvue has entered another stage of regulatory review. Documents on the European Commission’s website show that Kimberly-Clark has requested EU permission to complete the transaction, which was first announced in November 2025. The deal would combine Kimberly-Clark (NASDAQ:KMB) with a large portfolio of consumer-health brands, including Tylenol, […]",
                "category": "company",
                "datetime": 1788829402,
                "headline": "Can Kimberly-Clark Turn its $40 Billion Kenvue Bet into $2.1 Billion in Savings?"
              },
              {
                "id": 141771434,
                "url": "https://finnhub.io/api/news?id=aa27da536d50efd6679bcfd77d715631ee64f99862603b3e3817532e17f0638d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "KVUE nears its planned combination after shareholder and U.S. antitrust clearances, while margin, debt and legal risks temper the Q4 2026 outlook.",
                "category": "company",
                "datetime": 1788809280,
                "headline": "Kenvue's Kimberly-Clark Deal Nears Closing With Key Risks Still Ahead"
              },
              {
                "id": 141771435,
                "url": "https://finnhub.io/api/news?id=c7fb779f54328c36dd6407d82131e651780d8d24dbeab0820fdfc8bbec803f7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue's profit margins and cash flow improved in the first half, but modest sales growth, debt and uneven segment trends keep the risk-reward balanced.",
                "category": "company",
                "datetime": 1788809160,
                "headline": "Should Investors Buy KVUE as Margin Gains Offset Slow Sales Growth?"
              },
              {
                "id": 141364398,
                "url": "https://finnhub.io/api/news?id=09d17b13a3b9623d1cbaf1c6affe0168839e4c7814c7d78cf92b2d3e5cbbcdb8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Deal skepticism and litigation fears still weigh on this consumer staples stalwart.",
                "category": "company",
                "datetime": 1788186900,
                "headline": "This Dividend King Just Offered a Buy-the-Dip Opportunity"
              },
              {
                "id": 141336283,
                "url": "https://finnhub.io/api/news?id=d92db7b94ab38deb8d45bd11ce337de7df789b48d477823807203626cf4038b8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215519735/image_2215519735.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "KVUE",
                "summary": "Dividend Aristocrats (NOBL) nearly match SPY in 2026, with top gainers, rising dividend growth, and 29 undervalued picks—see which to buy now.",
                "category": "company",
                "datetime": 1787894920,
                "headline": "Best Dividend Aristocrats For September 2026"
              },
              {
                "id": 141364399,
                "url": "https://finnhub.io/api/news?id=0cdf3bbf82fd4d3692b991366108d2d79958c3da74c34e9b945ade1fee13dd52",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kimberly-Clark (KMB) stock is in focus after the company named Suzana Blades as Senior Vice President and General Counsel, with a future role tied to its pending acquisition of Kenvue Inc. Kimberly-Clark shares trade at US$110.34, with the stock up 10.2% over the past 90 days and 8.8% year to date on a share price basis, even though the 1 year total shareholder return has declined 11.1%. This points to improving short term momentum alongside a weaker longer term experience for...",
                "category": "company",
                "datetime": 1787846798,
                "headline": "Kimberly Clark (KMB) Names New Legal Chief As Kenvue Deal Puts Valuation In Focus"
              },
              {
                "id": 141364401,
                "url": "https://finnhub.io/api/news?id=7d1eb0210e7bb49c050819cf974eab94fa77135ae900c69af885597380b1861d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Pure Strategies, a sustainability consulting firm empowering brands and retailers to realize meaningful environmental and social improvement, is offering a full day of workshops, panels, and small group discussions during Climate Week NYC. The \"Day of Action\" program, being held Wednesday, September 23, 2026, is designed to help companies advance climate and nature strategies and turn sustainability investment into measurable returns.",
                "category": "company",
                "datetime": 1787775420,
                "headline": "Pure Strategies Announces \"Day of Action\" Full Day Program during Climate Week NYC - September 23, 2026"
              },
              {
                "id": 141324202,
                "url": "https://finnhub.io/api/news?id=c710f4da94ba6b1816de5555e8b2151446aae51f52ce20fa254d5a2921bdc8fd",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "KVUE",
                "summary": "Stay informed about the most active stocks in the S&P500 index on Wednesday's session. Discover the stocks that are generating the highest trading volume and driving market activity.",
                "category": "company",
                "datetime": 1787767501,
                "headline": "Explore the S&P500 index on Wednesday and find out which stocks are the most active in today's session."
              },
              {
                "id": 141312616,
                "url": "https://finnhub.io/api/news?id=041f861e37772b1094116dba0988f23039993625d6d2ef845d0a2ee0d16a1e4d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/458559027/image_458559027.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "KVUE",
                "summary": "Kenvue Inc. upgraded to a soft buy as the Kimberly-Clark Corporation merger looks likely. Click for this updated look at KVUE and KMB as they seek to join.",
                "category": "company",
                "datetime": 1787599909,
                "headline": "Kenvue Deserves Some Love As Its Purchase By Kimberly-Clark Looks Imminent"
              },
              {
                "id": 141364400,
                "url": "https://finnhub.io/api/news?id=f57b06989658200ab5d2eae0097a7252b38920e5534a9d42d5ec6e6a1c7b2034",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "In a challenge brought by Kenvue Inc., BBB National Programs’ National Advertising Division determined that Hims & Hers Health, Inc. provided a reasonable basis for its comparative efficacy claim. However, the National Advertising Division (NAD) recommended that it modify or discontinue other claims regarding doctor-trusted ingredients, dermatologist recommendations, safety and side effects.New York, NY, Aug. 24, 2026 (GLOBE NEWSWIRE) -- In a challenge brought by Kenvue Inc., BBB National Progra",
                "category": "company",
                "datetime": 1787594400,
                "headline": "National Advertising Division Finds Hims & Hers Has Support for Combination Efficacy Message; Recommends Modification or Discontinuance of Other Claims"
              },
              {
                "id": 141310775,
                "url": "https://finnhub.io/api/news?id=8ebad401400c6591cbad60ecd91bb62c4623c346f30482ec02166fddb02adf4f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2257340277/image_2257340277.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "KVUE",
                "summary": "Kenvue Inc.’s KMB buyout faces China SAMR Phase 2 antitrust review. Click for more on KVUE and how this affects whether you should invest in KVUE stock.",
                "category": "company",
                "datetime": 1787586192,
                "headline": "Kenvue: Acquisition By Kimberly-Clark Hit An Obstacle - What Now"
              },
              {
                "id": 141364402,
                "url": "https://finnhub.io/api/news?id=730a9ed2aaaaa65bb9c2e979496358c87934786262e81db479e74c94f7a9899f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "The beauty group's repricing rests on a profit plan it controls, while the low end of its new sales guidance is no faster than the year just ended.",
                "category": "company",
                "datetime": 1787585240,
                "headline": "Estee Lauder Stock Jumped On A Bigger Margin Promise"
              },
              {
                "id": 141307500,
                "url": "https://finnhub.io/api/news?id=32b08bbe296e7cb212fd1ae7c5aebca8ee10a12f8968f1cb43ac3b54896393a6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2260312486/image_2260312486.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "KVUE",
                "summary": "Dividend Kings beat the S&P 500 YTD, with 30 topping SPY and 25 looking undervalued with 10%+ return potential.",
                "category": "company",
                "datetime": 1787547151,
                "headline": "Best Dividend Kings: August 2026"
              },
              {
                "id": 141282754,
                "url": "https://finnhub.io/api/news?id=d6e8702ffd287b3173c9163b137bb8ec42a1739ff848e40850de334af327d7ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue stock has delivered a 9.3% gain year to date. Its current share price of US$18.93 still sits well below an intrinsic value estimate from a Discounted Cash Flow (DCF) model, which points to a 36.4% discount. At the same time, traditional earnings multiples suggest the shares look about fairly priced, leaving investors weighing a clear DCF upside signal against more neutral market ratios. Year to date, Kenvue is up 9.3%, indicating the market has already repriced the stock higher even...",
                "category": "company",
                "datetime": 1787292615,
                "headline": "Kenvue (KVUE) Stock Looks Cheap On Cash Flow But Fair On Earnings"
              },
              {
                "id": 141282755,
                "url": "https://finnhub.io/api/news?id=a45b9ab18c80eae5ef52d4897040a916581758913448bcfaed72ddb23667f08f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "In August 2026, Kenvue’s Zyrtec brand launched Zyrtec Allergen Shield Spray, a drug-free nasal mist that forms a gel barrier in the nose within minutes to help block common airborne allergens like pollen, pet dander, and dust for up to six hours in adults and children aged 12 and older. This first-of-its-kind, HPMC-based spray expands Zyrtec’s toolkit toward proactive allergen defense, signaling Kenvue’s push into drug-free, preventative allergy solutions. We’ll now examine how this new...",
                "category": "company",
                "datetime": 1787271185,
                "headline": "Should Zyrtec’s New Drug-Free Allergen Shield Spray Launch Require Action From Kenvue (KVUE) Investors?"
              },
              {
                "id": 141278128,
                "url": "https://finnhub.io/api/news?id=6ae953c0c2a0889b6642fd3164e527ee58f54d9cc09703b5237c69b976de98ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Johnson & Johnson's new drugs may offset declining sales due to patent-protection losses.",
                "category": "company",
                "datetime": 1787242320,
                "headline": "Johnson & Johnson Just Sent Shareholders an Important 11-Word Message About Its Future"
              },
              {
                "id": 141282763,
                "url": "https://finnhub.io/api/news?id=adbbcf502704dea0876fa7d6c12f56918adec15fb19170df8f68192c3d1726d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Panettiere's death has re-ignited calls to boycott Neutrogena, which she said ended a partnership after she spoke out about postpartum depression.",
                "category": "company",
                "datetime": 1787239528,
                "headline": "Will a Neutrogena boycott by Hayden Panettiere's fans work?"
              },
              {
                "id": 141282756,
                "url": "https://finnhub.io/api/news?id=f7e9f9af2724ae75a24bbee4208fcfc80ce1a514f2e2f949f1a3e6ffa79e11d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Zyrtec Allergen Shield Spray, a new drug free nasal mist from Kenvue (KVUE), has given investors fresh product news to weigh. The launch highlights activity in the company’s Self Care allergy portfolio. See our latest analysis for Kenvue. The recent Zyrtec Allergen Shield Spray launch comes after Kenvue reported second quarter 2026 sales of US$3,955 million and net income of US$456 million on August 6, while also completing a US$439.14 million share repurchase program that covered 20,387,000...",
                "category": "company",
                "datetime": 1787235222,
                "headline": "Kenvue (KVUE) Launches Zyrtec Spray As Its Undervalued Case Faces A Fresh Test"
              },
              {
                "id": 141282767,
                "url": "https://finnhub.io/api/news?id=059ca06eb53a909a27ad9eb14e946821ac0e6d252bd14713a5cb17ac4352d1be",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Hygiene and health company Essity has entered into an agreement to acquire Kenvue's feminine care business in Brazil, including the market-leading brands Carefree, Sempre Livre and o.b. The purchase price amounts to USD 284m (approximately SEK 2.7bn) on a cash and debt-free basis. The acquisition strengthens Essity's position as a market leader in feminine care in Latin America.",
                "category": "company",
                "datetime": 1787198760,
                "headline": "Essity acquires feminine care business in Brazil"
              },
              {
                "id": 141261729,
                "url": "https://finnhub.io/api/news?id=c88cc7e7cc91f6d0020d7de624a2c351fd92acbfd3808ec26302e04d766c0a55",
                "image": "",
                "source": "Benzinga",
                "related": "KVUE",
                "summary": "https://www.essity.com/media/press-release/essity-acquires-feminine-care-business-in-brazil/9dd724cebbb532f5/",
                "category": "company",
                "datetime": 1787144784,
                "headline": "Essity Strikes Agreement To Acquire Kenvue's Feminine Care Operations In Brazil For $284M"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 6,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.8,
            "source_article_count": 37,
            "discarded_article_count": 31
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 12.6,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 1.1,
          "macdPoints": 0.8,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.1,
            "vcp_reason": "跌縮量(近10日3日)；升放量(近10日2日)；Ready=N；Confirm=Y",
            "vcp_metrics": {
              "up_days": 3,
              "vol_ref": 24144633.333333332,
              "down_days": 6,
              "vcp_ready": false,
              "above_ma50": false,
              "avg_vol_10": 30684510,
              "avg_vol_20": 25817575,
              "avg_vol_30": 24144633.333333332,
              "range_pct_10": 0.08844866071428556,
              "range_pct_20": 0.10937499999999983,
              "range_pct_30": 0.11718749999999988,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.2708625381209628,
              "dist_to_20d_high": 0.08384458077709597,
              "down_shrink_days": 3,
              "breakout_level_20d": 19.56,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.7547619047619043
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 0.8,
          "volumeWeight": 2,
          "maCrossPoints": 0,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 1,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.8,
            "details": {
              "atrPct": 1.9017857142857142,
              "turnoverUsdM": 964.5332838400001,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1.2
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.KVUE",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 17.2384,
            "strength_details": {
              "ma_score": 1,
              "atr_score": 2.5,
              "rsi_score": 2.5,
              "macd_score": 1,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.3,
            "stop_loss_percent": 3.8,
            "take_profit_price": 18.816,
            "target_multiplier": 1.9,
            "technical_strength": 1.73,
            "take_profit_percent": 5
          },
          "positionPoints": 1.8,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Consumer Staples",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.3145539906103287,
          "stopLossPercent": 3.8035714285714284,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.KVUE",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 0.3408,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 8,
      "atr_pct": 1.9
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -127.52
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.1613
    },
    "kdj": {
      "d": 15.53,
      "j": 16.68,
      "k": 15.91,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "超賣或超買風險",
      "score": 2,
      "value": 24.1
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 47308502,
      "recentSlope": 4525660.2,
      "previousSlope": -7311400
    },
    "rsi": 22.13,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 18.5068,
      "position": "SAR喺價上",
      "distancePct": 3.27,
      "previousTrend": "下降"
    },
    "ma50": 19.0096,
    "macd": {
      "macd": -0.3269143485122079,
      "trend": "看跌",
      "signal": -0.2019110800519818,
      "histogram": -0.1250032684602261
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 18.5222,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.99,
      "score": 6,
      "avgVolume": 27110310,
      "currentVolume": 53824402
    },
    "derived": {
      "ma20": 18.713,
      "ma50": 19.0096,
      "prevClose": 17.91,
      "avgVolume10": 33359750,
      "avgVolume20": 27110310,
      "changePercent": 0.06,
      "avgVolumeForScore": 27110310
    },
    "ma_cross": {
      "ma20": 18.713,
      "ma50": 19.0096,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "熊勢",
      "score": 0,
      "prevMa20": 18.7565,
      "prevMa50": 19.0424,
      "spreadPct": 1.56,
      "isVolumeBreakout": true
    },
    "bollinger": {
      "lower": 17.5963,
      "upper": 19.8297,
      "position": "中間"
    },
    "rsi_short": 15.25,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.99
    }
  }
}

Raw metrics JSON

 
{
  "close": 17.92,
  "volume": 53824402,
  "changePercent": 0.06
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.